Form D · Biotechnology
OrsoBio, Inc.
Menlo Park, CA · CIK 0002000354
Offering snapshot reported Aug 28, 2024 · SEC filing
- Reported sold
- $40M Offering amount: $67M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 14, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 28, 2024 | Initial | $40,000,000 | No comparison | 7 | SEC filing |
| Nov 13, 2023 | Initial | $84,629,383 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-522654
Source: Form D, filed Aug 28, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Srinivas Akkaraju | Director |
| Edward Fleming | Director |
| Cory Freedland | Director |
| Gangadhara Ganapati | Director, Executive |
| Muzammil Mansuri | Director |
| Evan Rachlin | Director |
| Mani Subramanian | Director, Executive |
| Matthew Young | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 Jefferson Dr 1 St Floor Ste 124
Menlo Park, CA, 94025
Menlo Park, CA, 94025